tetano
Editor, Senior Moderator
Cell Rep
. 2021 Mar 6;108890.
doi: 10.1016/j.celrep.2021.108890. Online ahead of print.
The effect of spike mutations on SARS-CoV-2 neutralization
Chloe Rees-Spear[SUP] 1 [/SUP], Luke Muir[SUP] 1 [/SUP], Sarah A Griffith[SUP] 1 [/SUP], Judith Heaney[SUP] 2 [/SUP], Yoann Aldon[SUP] 3 [/SUP], Jonne L Snitselaar[SUP] 3 [/SUP], Peter Thomas[SUP] 1 [/SUP], Carl Graham[SUP] 4 [/SUP], Jeffrey Seow[SUP] 4 [/SUP], Nayung Lee[SUP] 1 [/SUP], Annachiara Rosa[SUP] 5 [/SUP], Chloe Roustan[SUP] 5 [/SUP], Catherine F Houlihan[SUP] 6 [/SUP], Rogier W Sanders[SUP] 3 [/SUP], Ravindra K Gupta[SUP] 7 [/SUP], Peter Cherepanov[SUP] 5 [/SUP], Hans J Stauss[SUP] 1 [/SUP], Eleni Nastouli[SUP] 8 [/SUP], SAFER Investigators; Katie J Doores[SUP] 4 [/SUP], Marit J van Gils[SUP] 3 [/SUP], Laura E McCoy[SUP] 9 [/SUP]
Affiliations
Abstract
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy.
Keywords: B.1.1.7; SARS-CoV-2; antibodies; immune escape; neutralization; serology; variant.
. 2021 Mar 6;108890.
doi: 10.1016/j.celrep.2021.108890. Online ahead of print.
The effect of spike mutations on SARS-CoV-2 neutralization
Chloe Rees-Spear[SUP] 1 [/SUP], Luke Muir[SUP] 1 [/SUP], Sarah A Griffith[SUP] 1 [/SUP], Judith Heaney[SUP] 2 [/SUP], Yoann Aldon[SUP] 3 [/SUP], Jonne L Snitselaar[SUP] 3 [/SUP], Peter Thomas[SUP] 1 [/SUP], Carl Graham[SUP] 4 [/SUP], Jeffrey Seow[SUP] 4 [/SUP], Nayung Lee[SUP] 1 [/SUP], Annachiara Rosa[SUP] 5 [/SUP], Chloe Roustan[SUP] 5 [/SUP], Catherine F Houlihan[SUP] 6 [/SUP], Rogier W Sanders[SUP] 3 [/SUP], Ravindra K Gupta[SUP] 7 [/SUP], Peter Cherepanov[SUP] 5 [/SUP], Hans J Stauss[SUP] 1 [/SUP], Eleni Nastouli[SUP] 8 [/SUP], SAFER Investigators; Katie J Doores[SUP] 4 [/SUP], Marit J van Gils[SUP] 3 [/SUP], Laura E McCoy[SUP] 9 [/SUP]
Affiliations
- PMID: 33713594
- DOI: 10.1016/j.celrep.2021.108890
Abstract
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy.
Keywords: B.1.1.7; SARS-CoV-2; antibodies; immune escape; neutralization; serology; variant.